These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38592145)
1. Associating Appendicitis with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Novel Insight into an Unexpected Connection. Roderburg C; Waldschmidt D; Leyh C; Krieg S; Krieg A; Luedde T; Loosen SH; Kostev K J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592145 [TBL] [Abstract][Full Text] [Related]
2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up. Choe HJ; Moon JH; Kim W; Koo BK; Cho NH Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957 [TBL] [Abstract][Full Text] [Related]
3. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups. Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448 [TBL] [Abstract][Full Text] [Related]
4. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A; Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202 [TBL] [Abstract][Full Text] [Related]
5. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up. Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD Hepatology; 2024 May; ():. PubMed ID: 38739848 [TBL] [Abstract][Full Text] [Related]
6. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Backer S; Khanna D Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470 [TBL] [Abstract][Full Text] [Related]
7. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality. Oh R; Kim S; Cho SH; Kim J; Lee YB; Jin SM; Hur KY; Kim G; Kim JH Diabetes Metab J; 2024 Aug; ():. PubMed ID: 39197834 [TBL] [Abstract][Full Text] [Related]
8. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. Sripongpun P; Kaewdech A; Udompap P; Kim WR JHEP Rep; 2024 Oct; 6(10):101127. PubMed ID: 39290401 [TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study. Kim GA; Jeong S; Jang H; Lee DH; Joo SK; Kim W Liver Cancer; 2024 Aug; 13(4):426-437. PubMed ID: 39114758 [TBL] [Abstract][Full Text] [Related]
10. Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study. Oh J; Kim BK; Yoon JH; Lee HH; Park H; Lee J; Park Y; Yun B; Chung J Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335133 [No Abstract] [Full Text] [Related]
11. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843 [TBL] [Abstract][Full Text] [Related]
12. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. Mori K; Tanaka M; Sato T; Akiyama Y; Endo K; Ogawa T; Suzuki T; Aida H; Kawaharata W; Nakata K; Hosaka I; Umetsu A; Hanawa N; Furuhashi M Hepatol Res; 2024 Aug; ():. PubMed ID: 39110552 [TBL] [Abstract][Full Text] [Related]
13. Exploring the landscape of steatotic liver disease in the general US population. Ciardullo S; Carbone M; Invernizzi P; Perseghin G Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856 [TBL] [Abstract][Full Text] [Related]
14. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study. Park Y; Jung J; Han S; Kim GA Aliment Pharmacol Ther; 2024 Sep; ():. PubMed ID: 39304991 [TBL] [Abstract][Full Text] [Related]
15. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan. Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965 [TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876 [TBL] [Abstract][Full Text] [Related]
18. Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization. Saini A; Rutledge B; Damughatla AR; Rasheed M; Naylor P; Mutchnick M Healthcare (Basel); 2024 Jul; 12(15):. PubMed ID: 39120181 [TBL] [Abstract][Full Text] [Related]